Početna › Rak endometrija › Rhode Island
Kliničke studije za Rak endometrija u državi Rhode Island
14 studija za Rak endometrija traži sudionike na lokacijama u državi Rhode Island.
Gradovi u državi Rhode Island
Službeni tekst studije (engleski)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Women and Infants Hospital, Providence
- Roger Williams Medical Center, Providence
U tijeku regrutacijaFaza 2
Sve dobne skupine · Oba spola · Ažurirano 2. lis 2026. · NCT05564377Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- Women and Infants Hospital, Providence
U tijeku regrutacijaFaza 1
Od 18 godina i više · Žene · Ažurirano 2. lis 2026. · NCT05950464Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Rhode Island Hospital, Providence
- Women and Infants Hospital, Providence
U tijeku regrutacijaFaza 3
Od 18 godina i više · Žene · Ažurirano 2. lis 2026. · NCT07198074Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Women and Infants Hospital, Providence
U tijeku regrutacijaFaza 2
Od 18 godina i više · Žene · Ažurirano 28. ruj 2026. · NCT05112601Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Women and Infants Hospital, Providence
U tijeku regrutacijaFaza 2
Od 18 godina i više · Žene · Ažurirano 24. ruj 2026. · NCT05640999A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Women & Infants Hospital ( Site 5003), Providence
U tijeku regrutacijaFaza 3
Od 18 godina i više · Žene · Ažurirano 17. ruj 2026. · NCT06952504A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Women & Infants Hospital of Rhode Island, Providence
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Providence
U tijeku regrutacijaFaza 3
Od 18 godina i više · Žene · Ažurirano 3. ruj 2026. · NCT06989112Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Providence
U tijeku regrutacijaFaza 1/2
Od 18 do 130 godina · Oba spola · Ažurirano 21. kol 2026. · NCT05797168A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Women & Infants Hospital, Providence
U tijeku regrutacijaFaza 2
Od 18 godina i više · Žene · Ažurirano 21. kol 2026. · NCT05548296Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Women and Infants Hospital of Rhode Island, Providence
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 4. kol 2026. · NCT05579366Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Women & Infants Hospital, Providence
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 13. stu 2025. · NCT05997017A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Women & Infants Hospital, Providence
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 4. stu 2025. · NCT05902988SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Providence
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 28. lis 2025. · NCT03452774Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.